- Home
- SNTI vs NCRA Comparison
SNTI vs NCRA Comparison
Compare SNTI & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- NCRA
- Stock Information
- Founded
- SNTI 2016
- NCRA 2002
- Country
- SNTI United States
- NCRA Taiwan
- Employees
- SNTI N/A
- NCRA N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- NCRA Farming/Seeds/Milling
- Sector
- SNTI Health Care
- NCRA Consumer Staples
- Exchange
- SNTI Nasdaq
- NCRA Nasdaq
- Market Cap
- SNTI 85.3M
- NCRA 14.4M
- IPO Year
- SNTI N/A
- NCRA N/A
- Fundamental
- Price
- SNTI $2.11
- NCRA $1.01
- Analyst Decision
- SNTI Strong Buy
- NCRA
- Analyst Count
- SNTI 2
- NCRA 0
- Target Price
- SNTI $8.50
- NCRA N/A
- AVG Volume (30 Days)
- SNTI 369.7K
- NCRA 54.2K
- Earning Date
- SNTI 08-12-2025
- NCRA 08-13-2025
- Dividend Yield
- SNTI N/A
- NCRA N/A
- EPS Growth
- SNTI N/A
- NCRA N/A
- EPS
- SNTI N/A
- NCRA N/A
- Revenue
- SNTI N/A
- NCRA $16,647,379.00
- Revenue This Year
- SNTI N/A
- NCRA N/A
- Revenue Next Year
- SNTI $150.00
- NCRA N/A
- P/E Ratio
- SNTI N/A
- NCRA N/A
- Revenue Growth
- SNTI N/A
- NCRA N/A
- 52 Week Low
- SNTI $1.52
- NCRA $0.70
- 52 Week High
- SNTI $16.94
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- SNTI 34.04
- NCRA 50.60
- Support Level
- SNTI $1.90
- NCRA $0.87
- Resistance Level
- SNTI $3.40
- NCRA $1.05
- Average True Range (ATR)
- SNTI 0.42
- NCRA 0.07
- MACD
- SNTI -0.09
- NCRA -0.00
- Stochastic Oscillator
- SNTI 10.58
- NCRA 65.79
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.